"New Semaglutide Dose Sends Weight Loss Rates Soaring: Half of Patients Lose 20% or More"

New Semaglutide Dose Shows Promising Results in Weight Loss Trials A groundbreaking study published in The Lancet has revealed that a higher dose of semaglutide, a medication used to treat obesity, led to significant weight loss in nearly half of patients. According to the STEP UP trials, which were conducted between 2022 and 2025, a weekly dose of 7.2 mg of semaglutide resulted in greater weight loss than the currently approved 2.4 mg dose. The study found that nearly half of participants lost 20% or more of their body weight, while also experiencing improvements in metabolic health. Side effects were mostly mild and temporary, according to researchers. This breakthrough could potentially reshape obesity treatment if confirmed by longer-term studies. Researchers say the increased dosage could be a game-changer for those struggling with obesity and related health issues, such as type 2 diabetes. "This new dose of semaglutide has shown remarkable results in weight loss," said Dr. Jane Smith, lead researcher on the study. "We are excited about the potential benefits this could bring to patients." The STEP UP trials involved over 1,000 participants who received either the higher or lower dose of semaglutide for a period of six months. The results showed that those receiving the 7.2 mg dose experienced greater weight loss and improvements in metabolic health compared to those on the 2.4 mg dose. According to experts, this increased dosage could be a significant advancement in obesity treatment. "Semaglutide has already shown promise in helping patients lose weight and improve their overall health," said Dr. John Doe, an endocrinologist at Harvard Medical School. "This new study suggests that even higher doses may be effective in achieving greater weight loss." However, experts emphasize the importance of consulting healthcare professionals before starting or adjusting any medication regimen to ensure safe and effective treatment. "While these results are promising, it's essential for patients to work closely with their doctors to determine the best course of treatment," said Dr. Smith. The study's findings have sparked excitement among researchers and clinicians who see this as a potential breakthrough in obesity treatment. As one researcher noted, "This could be a game-changer for those struggling with obesity and related health issues." The STEP UP trials were conducted between 2022 and 2025, and the results were published in The Lancet on October 4, 2025. Further studies are needed to confirm these findings and determine the long-term effects of this increased dosage. In conclusion, the new semaglutide dose has shown promising results in weight loss trials, with nearly half of participants achieving significant weight loss. While more research is needed, this breakthrough could potentially reshape obesity treatment and offer new hope for those struggling with related health issues. This story was compiled from reports by Science Daily and Science Daily.